• No products in the cart.

Genetic Test

Exacta

INTRODUCTION

Cancer is a disease of the genes. Like every human being, each person’s cancer is unique. Unfortunately, conventional ‘Standard of Care’ approach does not take into consideration the overall genetic architecture of a particular patient’s tumor and consequently patients usually suffer due to failed therapies or aggressive relapse. It is thus imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan, especially where treatments are failing or even the Standard of Care options are unsatisfactory.

About Exacta

Exacta® is an intensive and in depth tumor gene expression analysis. It analyses 100s of millions of data points at the molecular level to reveal all possible targets for precision drugs. Exacta® is one of the most powerful tumor investigation and is an extreme analytical tool that reveals the driven mutations and pathways driving a person’s cancer. Exacta is best molecular analysis for difficult cancers.

Features of Exacta

  • Determines deepest genetic secrets of an individual patient’s cancer.
  • Accurate, multi-coordinate analysis of all 22,000 genes in the cancer genome.
  • Reaches the depths of cancer’s mechanism through 100’s of millions of data points.
  • Reveals mutations and pathways that are propelling a particular cancer in an individual.
  • Enables a highly sophisticated treatment strategy beyond conventional perspective.

TruBlood

INTRODUCTION

TrubloodTM is a revolutionary Encyclopedic Liquid Biopsy that aims to substitute invasive tissue extraction for all cancers. Conceptualized and developed by Datar Cancer Genetics Ltd by efforts of several dozen scientist working relentlessly for the last five years, Trublood has been validated over thousands of samples – both from asymptomatic individuals and cancer patients.

  • trublood™ is a non-Invasive, blood-based investigation for symotomatlc individuals who have been advised a biopsy to check for malignancy.
  • trublood™ can also be considered for patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations.
  • trublood™ is also recommended in case of suspected metastatic relapse to rule out new primary.
  • trublood™ utilises a proprietary technique to capture Circulating Tumor Cells from the blood with extremely high efficiency as well as permits Genomic Analysis of Circulating Tumor DNA.
  • Diagnostic determination i.e. malignant I non-malignant
    Organ of origin confirmation
  • Classification viz. Adenocarcinoma I Squamous cell carcinoma etc.
  • Sub-classification viz. Hormone Receptor +ve I -ve etc.
  • lmmuno-cytochemistry for treatment guidance
  • FISH
  • ctDNA (Circulating Tumor DNA)

Cancer Track

INTRODUCTION

Till now, tissue biopsies represent the standard test of tumor diagnosis. Unfortunately tissue biopsy only reflects a single point in time of a single site of the tumor. This inadequacy for the comprehensive characterization of a patient’s tumor can be overcome with liquid biopsy.

We at Datar Cancer Genetics Limited offer you CancertrackTM which is a non-invasive blood test that detects cancer cells and their fragments with ultra-high precision, specificity and reliability. This test checks for cancerous cells / cancer cell fragments to monitor the disease / recurrence or to keep an eye on changes in the tumor characteristics, as often as necessary, without the cost, risk and consequences of radiation from scans, hospitalization, anesthesia or painful surgical biopsies.

  • Utilizes multi-coordinate and multidimensional probes to track down the tiniest of fragments of cells / DNA / RNA released by cancer cells in the patient’s blood
  • Possesses unique and unprecedented capability to detect cancerous activity
  • Enables a rapid response in real-time to the dynamic molecular profile of a patient’s cancer
  • Safe, sure, simple and cost-effective
  • Non-invasive blood test
  • Not dependent on availability of tissue
  • Rapid lab result
  • Tests all active disease sites
  • Limits of detection is 0.1% MAF
  • Far more powerful than conventional biopsy
  • 100% coverage of NCCN biomarkers
  • All clinically significant findings re-confirmed by separate platform

Gliotrack

INTRODUCTION

The need for minimally invasive approaches for diagnosis and monitoring of brain tumors for both primary and metastatic disease has prompted the emergence of liquid biopsy. Liquid biopsy offers technologic advancements for the measurement of  Airculating tumor biomarkers with continued refinements in standardization and improved signal detection. Datar Cancer Genetics Limited is committed to growing this area of molecular analysis.

Gliotrack™ detects tumor biomarkers like cell free tumor DNA (ctDNA), mRNA and microRNA released by the tumor cells in peripheral blood of the patient. Cell free tumor DNA (ctDNA) is released by the dying tumor cells whereas mRNA and microRNA are actively secreted in the form of exosomes by the live tumor cells.

Several circulating biomarkers in the peripheral blood such as circulating tumor cells, tumor derived cell free DNA (ctDNA), tumor derived micro-vesicles called exosomes are considered in recent years for their use in non-invasive assessment of tumor derived molecular artifacts due to their high sensitivity and specificity. The analysis of circulating, cell free DNA is one of the most promising technical advances to provide an alternative to tumor biopsy.

  • Patients with suspected glioma on MRI.
  • Patients with glioma who are unfit for biopsy e.g. Diffuse intrinsic pontine glioma or associated comorbidities.
  • Patients with inadequate tissue sample for molecular stratification / prognostication.
  • Diagnosed glioma patients – to select optimum therapy or to monitor therapy response .
  • Patients on treatment – to distinguish true disease progression from treatment associated changes like radiation necrosis and to monitor residual disease.
  • Patients in remission – to detect recurrence at the earliest.

Liquid Biopsy For Lung Cancer

INTRODUCTION

Liquid biopsy, a noninvasive alternative to tissue biopsy, provides real-time monitoring of lung cancer via more frequent analysis of circulating biomarkers, such as circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).

Datar Cancer Genetics Limited offers a more comprehensive picture of the disease that may reflect the status of the disease better and thereby contribute to more personalized treatment than tissue analysis.

  • Non-invasive biopsy for lung cancer mutation analysis
  • Inadequacy of tumor tissue is no longer a problem for targeted therapy selection
  • Patients unfit for invasive biopsy can still avail benefit of targeted therapies
  • Addresses problem of tumor heterogeneity
  • Helps in real-time disease monitoring and tumor evolution tracking
  • Therapy failure, due to acquired resistance mutations, can be detected prior to clinical/radiological disease progression
  • Gives information about tumor burden and molecular residual disease
  • Helps to know presence of acquired resistance mutations
  • High sensitivity (96.4%) and specificity (100%)
  • ASCO 2016 endorsed a liquid biopsy for tumor mutation analysis with respect

Geneshield

INTRODUCTION

Pharmacokinetics and pharmacodynamics of a drug depends on complex processes that are coded by different genes influencing drug transport, metabolism, and mechanism of action. When gene mutation and polymorphisms occur, the drug affinity towards metabolic activity or receptors also differs. More than 75% of the metabolic interactions of drugs are mediated through Cytochrome P450. We analyse the gene variant related to the ubiquitous P450 group of genes besides other relevant alleles. Among the various factors that influence expression and function of the enzymes to predict pharmacokinetics and drug response, monogenic polymorphisms play a major part in the variability of enzymes.

Drugs are a significant cause of morbidity and mortality, induced by Adverse Drug Reactions (ADRs). Although, till recently, the efficacy of drugs and their possible reactions were largely speculative for a given individual, recent developments in genetic sequencing technology and bioinformatics have lifted the veil of uncertainty.

  • Provides insight into patient’s metabolic response
  • Surer, safer and selective drug therapy
  • Avoids Overdose / Underdose
  • Minimizes Adverse Drug Reactions (ADR)
  • Eliminates trial and error in therapy
  • Optimises therapeutic response
  • Affordable and once-in a-lifetime cost
  • Protects doctor from medicolegal complications

Personal Genome Analysis

INTRODUCTION

What can your DNA speak about your Health?

Human body cells have DNA, which influences many characteristics of the organism such as physical characteristics like height, colour of eyes, texture and colour of hair, etc. Human DNA encodes information for the processes that govern development, functioning and reproduction.

Gene represents certain specific stretches of DNA that are inherited from biological parents. These genes help to relate the characteristics of our parents and grandparents with us. They are the building blocks and everyone is born with a unique set of genes.

Datar Cancer Genetics Limited currently offers Personal Genome Analysis (PGA), which is a genetic test can analyse each pair of genes and identify changes in chromosomes or genes. These tests are called predictive tests, diagnostic tests, carrier tests and pharmacogenetic tests, based on their purpose. It is a modern genetic screening test that is performed on the DNA obtained from a person’s blood & saliva.

  • Determination of the disease predisposition of an individual
  • Determination of genetic makeup of an individual
  • Understand the impact of genes on diseases or conditions
  • DNA sequence and gives information about the disease or conditions

Drugs are a significant cause of morbidity and mortality, induced by Adverse Drug Reactions (ADRs). Although, till recently, the efficacy of drugs and their possible reactions were largely speculative for a given individual, recent developments in genetic sequencing technology and bioinformatics have lifted the veil of uncertainty.

  • Provides insight into patient’s metabolic response
  • Surer, safer and selective drug therapy
  • Avoids Overdose / Underdose
  • Minimizes Adverse Drug Reactions (ADR)
  • Eliminates trial and error in therapy
  • Optimises therapeutic response
  • Affordable and once-in a-lifetime cost
  • Protects doctor from medicolegal complications

Screengene

INTRODUCTION

Hereditary Cancer Syndromes are caused by faulty changes in genes called as “Hereditary Mutations”. These can be passed down from parent to child and cause cancer to run in the family, making it Hereditary Cancer.

  • Simultaneous analysis of multiple cancer predisposition genes
  • More time and cost-effective than single gene testing for patients suspicious for multiple hereditary cancer syndromes
  • A greater likelihood of identifying a hereditary cause for cancer
  • Avoidance of false negative assurance given by limited genetic screening, which can miss risk-causing genetic mutations in other genes
  • A complete diagnostic work-up in a timely fashion without multiple follow-up visits for additional test results

Drugs are a significant cause of morbidity and mortality, induced by Adverse Drug Reactions (ADRs). Although, till recently, the efficacy of drugs and their possible reactions were largely speculative for a given individual, recent developments in genetic sequencing technology and bioinformatics have lifted the veil of uncertainty.

  • Provides insight into patient’s metabolic response
  • Surer, safer and selective drug therapy
  • Avoids Overdose / Underdose
  • Minimizes Adverse Drug Reactions (ADR)
  • Eliminates trial and error in therapy
  • Optimises therapeutic response
  • Affordable and once-in a-lifetime cost
  • Protects doctor from medicolegal complications
View Cart Checkout Continue Shopping